RU.521 is a potent and selective cyclic GMP-AMP synthase (cGAS) inhibitor (Kd = 36.2 nM; IC50 values are 0.11 μM and 2.94 μM against m-cGAS and h-cGAS, respectively). RU.521 suppresses dsDNA-activated reporter activity but not 5'ppp-HP20 RNA or murine IFN-β-induced IFN-β1-dependent gene expression. RU.521 reduces constitutive expression of type I interferon in primary macrophages from a mouse model of Aicardi-Gouti?res syndrome. Pretreatment of chimeric antigen receptor (CAR) redirected T cells with RU.521 increases efficiency of virus-free gene editing by improving cell viability and CAR integration in cell line.
Caractéristiques techniques
| Marque | Tocris Bioscience |
| Réf. B-LABO | BL-RE-124466 |
| Réf. fabricant | 18736205 |
| Nom chimique ou matériau | 3-[1-(6,7-Dichloro-1 H-benzimidazol-2-yl)-5-hydroxy-3-methyl-1 H-pyrazol-4-yl]-1(3 H)-isobenzofuranone |
|---|
| CAS | 2262452-06-0 |
|---|
| Quantité | 10 mg |
|---|
| Cible | Synthase/Synthetase Inhibitors |
|---|
| Formule moléculaire | C<sub>19</sub>H<sub>12</sub>Cl<sub>2</sub>N<sub>4</sub>O<sub>3</sub> |
|---|
| Pureté | 0.98 |
Une question, une configuration particulière ?
Contactez-nous pour un devis.